Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

U0800000

Ursodeoxycholic acid

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

3α,7β-Dihydroxy-5β-cholan-24-oic acid, 5β-Cholan-24-oic acid-3α,7β-diol, 7β-Hydroxylithocholic acid, UDCS

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C24H40O4
Numero CAS:
128-13-2
Peso molecolare:
392.57
Beilstein:
3219888
Numero MDL:
MFCD00003680
Codice UNSPSC:
41116107
ID PubChem:
329827593
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

ursodeoxycholic acid

Produttore/marchio commerciale

EDQM

Punto di fusione

203-204 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1
RUDATBOHQWOJDD-UZVSRGJWSA-N

Informazioni sul gene

human ... NR1H4(9971)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Ursodeoxycholic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H315,H319

Classi di pericolo

Eye Irrit. 2 - Skin Irrit. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Chenodeoxycholic acid British Pharmacopoeia (BP) Reference Standard

BP926

Chenodeoxycholic acid

Deoxycholic Acid (Desoxycholic Acid) United States Pharmacopeia (USP) Reference Standard

USP

1171273

Deoxycholic Acid (Desoxycholic Acid)

Taurolithocholic acid 3-sulfate disodium salt

Sigma-Aldrich

T0512

Taurolithocholic acid 3-sulfate disodium salt

Tauroursodeoxycholic Acid, Sodium Salt Tauroursodeoxycholic is a detergent useful for the solubilization of lipids and membrane-bound proteins.

Millipore

580549

Tauroursodeoxycholic Acid, Sodium Salt

Chenodeoxycholic acid

Sigma-Aldrich

C9377

Chenodeoxycholic acid

Lithocholic acid ≥95%

Sigma-Aldrich

L6250

Lithocholic acid

Cholic acid from bovine and/or ovine, ≥98%

Sigma-Aldrich

C1129

Cholic acid

Deoxycholic acid ≥98% (HPLC)

Sigma-Aldrich

D2510

Deoxycholic acid

Marco Carbone et al.
Gastroenterology, 144(3), 560-569 (2012-12-19)
BACKGROUND, & AIMS: Studies of primary biliary cirrhosis (PBC) phenotypes largely have been performed using small and selected populations. Study size has precluded investigation of important disease subgroups, such as men and young patients. We used a national patient cohort
Li-Na Zhang et al.
Hepatology (Baltimore, Md.), 58(1), 264-272 (2013-02-15)
The biochemical response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis is a strong predictor of long-term outcome and thus facilitates the rapid identification of patients needing new therapeutic approaches. Numerous criteria for predicting outcome of treatment have been studied
R A Rubin et al.
Annals of internal medicine, 121(3), 207-218 (1994-08-01)
To explain the rationale supporting the use of ursodiol (ursodeoxycholic acid) for the treatment of patients with cholesterol gallstones and chronic liver diseases and to describe the results obtained in clinical trials. Personal databases of the authors and MEDLINE were
Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.
Keith Lindor
The New England journal of medicine, 357(15), 1524-1529 (2007-10-12)
Ursodeoxycholic acid in chronic hepatitis C.
Raoul Poupon et al.
Gut, 56(12), 1652-1653 (2007-11-14)
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.